What You Should Know:
– Vantive, formerly known as Baxter Kidney Care, today announced its launch as a new standalone company focused on vital organ therapies.
– The formation follows the completion of its acquisition by funds managed by Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). Building on a 70-year legacy of innovation in kidney care, Vantive is committed to extending lives and expanding possibilities for patients with kidney disease and other vital organ conditions.
Vantive to Elevate Dialysis and Expand into New Therapies
Vantive offers a comprehensive suite of products, digitally enhanced solutions, and advanced services to support dialysis at home and in the clinic, as well as critical care therapies for the kidney and other vital organs in the intensive care unit (ICU).
As an independent company, Vantive is dedicated to:
- Elevating the standard of care: Improving the dialysis experience and expanding access to life-sustaining therapies.
- Empowering patients and care teams: Providing innovative solutions that simplify and improve the therapy process.
- Expanding beyond kidney care: Investing in research and development to transform vital organ therapies.
With a presence in over 100 countries, Vantive’s people, solutions, and services interact with patients over 1 million times each day.
“From patients beginning their dialysis journeys to clinicians fighting to save lives in the ICU, accessing the right therapy at the right time is critical. This is why our singular focus as Vantive is to empower more patients and care teams in these moments – with better options, greater control and expanded possibilities,” said Chris Toth, CEO of Vantive. “We are beginning a new era of vital organ therapy innovation, and I am looking forward to working with our 23,000 global Vantive colleagues to make a difference for millions of patients and families around the world.”
